Immunotherapy Updates in GEJ and CRC

Immunotherapies are rapidly changing the standard of care for patients with cancer. Checkpoint inhibitors constitute a highly active area of research with numerous clinical trials underway to investigate the efficacy and safety of these agents, including many in combination trials with other immunotherapies, targeted therapies, chemotherapies, and/or radiation therapies. Results from these trials are reported on an almost daily basis, leaving busy clinicians scrambling to assess available evidence and identify the most promising approaches to treat their patients with advanced cancers.



The intended audience for this activity program are medical, surgical, and radiation oncologists, gastroenterologists, dermatologists, pulmonologists, primary care physicians, internal medicine specialists, oncology pharmacists, oncology advanced practice nurses and physician assistants, social workers and other HCPs who participate in the care of patients receiving immunotherapies.




Learning Objectives:

  • Discuss changes to the treatment algorithm and the issuance of updated guideline directed strategies to better incorporate immunotherapies into clinical practice
  • Evaluate the latest safety and efficacy data across checkpoint inhibitors for cancer treatment
  • Review new indications that expand the selection of treatment options
  • Integrate mitigation and management strategies for adverse events related to immunotherapies


Approximate Time to Complete: 60 minutes


Credit Available: January 25, 2022 - January 25, 2023


Developed through a collaboration between SITC and PlatformQ.




Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 1.00